| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8441372 | European Journal of Cancer | 2016 | 6 Pages |
Abstract
Tablet burden is considerable for many patients with MBC and can be problematic. A significant proportion of tablets represent treatment for co-morbidities, the significance of which may be questionable in women with MBC.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Marina Milic, Anna Foster, Karim Rihawi, Alan Anthoney, Chris Twelves,